NASDAQ:ZIOP - ZIOPHARM Oncology Stock Price, Forecast & News

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZIOP shares have decreased by 13.4% and is now trading at $2.20. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ZIOPHARM Oncology.

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for ZIOPHARM Oncology.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced its quarterly earnings results on Monday, March, 2nd. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. View ZIOPHARM Oncology's earnings history.

4 equities research analysts have issued 12 month price targets for ZIOPHARM Oncology's stock. Their forecasts range from $5.50 to $7.00. On average, they expect ZIOPHARM Oncology's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 184.1% from the stock's current price. View analysts' price targets for ZIOPHARM Oncology.

Press coverage about ZIOP stock has trended very negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZIOPHARM Oncology earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutZIOPHARM Oncology.

Some companies that are related to ZIOPHARM Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Intrexon (XON), Celgene (CELG), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), Amarin (AMRN), Arena Pharmaceuticals (ARNA), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK) and Sangamo Therapeutics (SGMO).

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ZIOP stock can currently be purchased for approximately $2.20.

ZIOPHARM Oncology has a market capitalization of $468.60 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-117,800,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe. View additional information about ZIOPHARM Oncology.

The official website for ZIOPHARM Oncology is http://www.ziopharm.com/.

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]